Trilogie was founded to solve a critical gap in ubiquitin-proteasome system (UPS) research: the paucity of high-specific-activity, biologically validated reagents and services that reflect the true complexity of UPS biology. Whether you’re mapping E3-substrate interactions, screening DUB inhibitors, or engineering protein degraders, we believe experimental outcomes depend on functional precision, starting with the reagents themselves.
Our focus:
Expression scouting and optimization for ligases, substrates, adaptors, and complex UPS proteins
Mechanism-aligned assay development for ubiquitylation cascades and degrader mode-of-action studies
Growing catalog of ready-to-use UPS tools designed to support academic and drug discovery researchers with reagents that perform reliably
Company Details
- Employees
- 5
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://trilogiebio.com/
Trilogie Bioscience Questions
Trilogie Bioscience's website is https://trilogiebio.com/
Trilogie Bioscience's LinkedIn profile is https://www.linkedin.com/company/trilogie-bioscience
Trilogie Bioscience has
5 employees.
View email and phone details for 5
employees at Trilogie Bioscience.
Trilogie Bioscience's industry is
Biotechnology Research
Trilogie Bioscience's top competitors are
Dunad Therapeutics,
Matrisome Bio,
Vertex Pharmaceuticals,
Nona Biosciences,
Calluna Pharma,
Metaphore Biotechnologies,
Conifer Life Sciences Group, Llc,
Abbvie,
Massachusetts Biomedical Initiatives (Mbi),
Conigen Bioscience, Inc..
Trilogie Bioscience's categories are Biotechnology Research
Trilogie Bioscience's founding year is 2024
